跳至主要内容
临床试验/NCT01143389
NCT01143389已完成2 期

Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia

Price Vision Group1 个研究点 分布在 1 个国家目标入组 510 人开始时间: 2010年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
510
试验地点
1
主要终点
Change in Maximum Keratometry From Baseline to 6 Months After Treatment

研究概览

简要总结

The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.

详细描述

The primary objective of this study is to evaluate two riboflavin-dosing regimens for corneal collagen cross-linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive ectasia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
10 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 10 years of age or older
  • Having documented ectasia on topography or tomography after previous refractive surgery OR progressive keratoconus defined as one or more of the following changes over a period of 36 months or less before randomization:
  • An increase of ≥ 1.00 D in the steepest keratometry value (or sim K)
  • An increase of ≥ 1.00 D in regular astigmatism evaluated by subjective manifest refraction
  • A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective manifest refraction
  • Documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia.
  • Subjects with keratoconus diagnosis only:
  • a. Axial topography consistent with keratoconus b. Presence of central or inferior steepening on the Pentacam map. c. Presence of one or more slit lamp findings associated with keratoconus, such as: i. Fleischer ring ii. Vogt striae iii. Corneal thinning iv. Corneal scarring
  • Contact Lens Wearers Only: Removal of contact lenses for the required period of time prior to the screening refraction:
  • Contact Lens Type Minimum Discontinuation Time Soft 3 Days Soft Extended Wear 1 Week Soft Toric 2 Weeks Rigid gas permeable 2 Weeks
  • Signed written informed consent

排除标准

  • Any keratoconus patient over 21 years of age without evidence of progression of his corneal deformity.
  • Patients with excessively thin corneas.
  • Previous ocular condition in the eyes to be treated that may predispose the eye for future complications, for example:
  • a. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) b. Clinically significant corneal scarring in the proposed treatment zone
  • A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.
  • A known sensitivity to treatment medications.
  • Patients with a current condition that, in the treating physician's opinion, would interfere with or prolong epithelial healing.
  • Pregnancy (including plan to become pregnant) or lactation during the course of the study

研究组 & 干预措施

Riboflavin 0.1% eyedrops every 5 minutes

Active Comparator

The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).

干预措施: Riboflavin (Drug)

Riboflavin 0.1% eyedrops every 5 minutes

Active Comparator

The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).

干预措施: UVX light (Device)

Riboflavin 0.1% eyedrops every 2 minutes

Active Comparator

The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).

干预措施: Riboflavin (Drug)

Riboflavin 0.1% eyedrops every 2 minutes

Active Comparator

The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).

干预措施: UVX light (Device)

结局指标

主要结局

Change in Maximum Keratometry From Baseline to 6 Months After Treatment

时间窗: 6 months

Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.

次要结局

  • Corrected Distance Visual Acuity (CDVA)(6 months)
  • Uncorrected Distance Visual Acuity (UDVA)(6 months)
  • Pachymetry(6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Corneal Crosslinking in Patients With Keratoconus... | 临床试验